https://www.biopharmawatch.com/news/MRNA/moderna-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T00:00:00.000Z Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026 https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-third-quarter-results-2026 BiopharmaWatch en 2026-10-28T00:00:00.000Z ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-host-conference-call-report-week-16-data-orka BiopharmaWatch en 2026-10-25T16:00:00.000Z Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026 https://www.biopharmawatch.com/news/SMMT/ivonescimab-chemotherapy-advanced-biliary-tract-cancer BiopharmaWatch en 2026-10-25T15:52:00.000Z Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China https://www.biopharmawatch.com/news/JNJ/rybrevant-faspro-amivantamab-hyaluronidase-lpuj-combination-demonstrates-77-overall BiopharmaWatch en 2026-10-25T13:45:00.000Z RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer https://www.biopharmawatch.com/news/JNJ/rybrevant-faspro-head-neck-cancer-response-rate BiopharmaWatch en 2026-10-25T13:45:00.000Z RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer https://www.biopharmawatch.com/news/AVBP/arrivent-phase-1-data-cdh17-targeted-adc-arr-217 BiopharmaWatch en 2026-10-25T13:00:00.000Z ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026 https://www.biopharmawatch.com/news/AMRN/amarin-update-phase-3-epa-metastasis-trial-emt2 BiopharmaWatch en 2026-10-25T12:11:00.000Z Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM) https://www.biopharmawatch.com/news/AGEN/agenus-phase-2-results-neoasiss-study BiopharmaWatch en 2026-10-25T11:00:00.000Z Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026 https://www.biopharmawatch.com/news/GMAB/genmab-phase-2-study-petosemtamab-colorectal-cancer BiopharmaWatch en 2026-10-25T11:00:00.000Z Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer https://www.biopharmawatch.com/news/NBP/novabridge-biosciences-givastomig-phase-1b-data-esmo-2026 BiopharmaWatch en 2026-10-25T11:00:00.000Z NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-survival-benefit-cscc BiopharmaWatch en 2026-10-25T09:15:00.000Z Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) https://www.biopharmawatch.com/news/XNCR/xencor-phase-1-xmab819-clear-cell-renal-cancer BiopharmaWatch en 2026-10-25T08:35:00.000Z Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors https://www.biopharmawatch.com/news/LLY/lilly-olomorasib-esmo-2026-data BiopharmaWatch en 2026-10-25T07:30:00.000Z New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer https://www.biopharmawatch.com/news/JNJ/jnj-6143-prostate-cancer-phase-1-results BiopharmaWatch en 2026-10-25T07:30:00.000Z Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule https://www.biopharmawatch.com/news/BNTX/biontech-bristol-myers-squibb-pumitamig-phase-2-data BiopharmaWatch en 2026-10-25T07:30:00.000Z BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy https://www.biopharmawatch.com/news/CLYM/climb-bio-budoprutug-phase-2-data-asn-kidney-week-2026 BiopharmaWatch en 2026-10-24T23:30:00.000Z Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/PFE/pfizer-25-valent-pneumococcal-vaccine-phase-2-results BiopharmaWatch en 2026-10-24T15:18:00.000Z Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026 https://www.biopharmawatch.com/news/AMGN/imdelltra-imfinzi-small-cell-lung-cancer-results BiopharmaWatch en 2026-10-24T14:30:00.000Z IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER https://www.biopharmawatch.com/news/JNJ/apalutamide-reduces-recurrence-risk-prostate-cancer BiopharmaWatch en 2026-10-24T13:01:00.000Z Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-erleada-apalutamide-treatment-surgery-reduces-risk-recurrence BiopharmaWatch en 2026-10-24T12:54:00.000Z Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer https://www.biopharmawatch.com/news/PBLS/parabilis-medicines-zolucatetide-phase-1-2-data BiopharmaWatch en 2026-10-24T12:45:00.000Z Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors https://www.biopharmawatch.com/news/GMAB/incyte-genmab-clinical-trial-collaboration BiopharmaWatch en 2026-10-24T11:00:00.000Z Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer https://www.biopharmawatch.com/news/GMAB/genmab-incyte-clinical-trial-metastatic-colorectal-cancer BiopharmaWatch en 2026-10-24T11:00:00.000Z Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer https://www.biopharmawatch.com/news/NBTX/nanobiotix-phase-1-study-nbtxr3-melanoma-results BiopharmaWatch en 2026-10-24T11:00:00.000Z NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma https://www.biopharmawatch.com/news/ONC/beone-presents-data-esmo-2026 BiopharmaWatch en 2026-10-24T08:15:00.000Z BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026 https://www.biopharmawatch.com/news/CELC/celcuity-updated-results-viktoria-1-study-esmo-2026 BiopharmaWatch en 2026-10-24T08:15:00.000Z Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026 https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-companion-002-results-tovecimig BiopharmaWatch en 2026-10-24T08:15:00.000Z Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026 https://www.biopharmawatch.com/news/LLY/lilly-sofetabart-mipitecan-esmo-2026 BiopharmaWatch en 2026-10-24T06:30:00.000Z Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026 https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-new-phase-1-data-folate-receptor-alpha-targeting BiopharmaWatch en 2026-10-24T06:30:00.000Z Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026 https://www.biopharmawatch.com/news/IMTX/immatics-clinical-activity-ima402-ima203cd8-esmo-2026 BiopharmaWatch en 2026-10-24T06:30:00.000Z Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting https://www.biopharmawatch.com/news/RXST/rxsight-reports-inducement-grants-permitted-nasdaq-listing-rules BiopharmaWatch en 2026-10-24T00:00:00.000Z RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules https://www.biopharmawatch.com/news/TVTX/travere-new-biomarker-data-asn-kidney-week BiopharmaWatch en 2026-10-23T23:20:00.000Z Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-inducement-grants BiopharmaWatch en 2026-10-23T21:00:00.000Z AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-lunit-ai-scope-io-agreement BiopharmaWatch en 2026-10-23T20:37:00.000Z Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-inducement-grants-october-2026 BiopharmaWatch en 2026-10-23T20:15:00.000Z Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SRTA/strata-critical-medical-q3-2026-earnings-call BiopharmaWatch en 2026-10-23T20:05:00.000Z Strata Critical Medical Schedules Third Quarter 2026 Earnings Conference Call https://www.biopharmawatch.com/news/WGS/genedx-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-23T20:05:00.000Z GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026 https://www.biopharmawatch.com/news/CPIX/cumberland-ifetroban-assist-ssc-trial-results BiopharmaWatch en 2026-10-23T20:05:00.000Z Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results https://www.biopharmawatch.com/news/ARDX/ardelyx-xphozah-serum-phosphate-reductions-asn-2026 BiopharmaWatch en 2026-10-23T20:01:00.000Z Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders https://www.biopharmawatch.com/news/CLYM/climb-bio-mabworks-clym116-mil116-asn-kidney-week-2026 BiopharmaWatch en 2026-10-23T20:01:00.000Z Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/ENSG/ensign-group-q3-2026-earnings-call BiopharmaWatch en 2026-10-23T20:01:00.000Z The Ensign Group Schedules Third Quarter 2026 Earnings Call for Wednesday, October 28, 2026 https://www.biopharmawatch.com/news/OFIX/orthofix-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-23T20:00:00.000Z Orthofix to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AVBP/arrivent-phase-1-data-esmo-2026 BiopharmaWatch en 2026-10-23T20:00:00.000Z ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026 https://www.biopharmawatch.com/news/ABBV/fda-approves-skyrizi-subcutaneous-induction-crohns-disease BiopharmaWatch en 2026-10-23T19:33:00.000Z U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease